Weight loss drug is not taking easy way out

Oprah Winfrey reveals taking GLP-1 weight-loss drug made her realize what she got wrong about ‘thin people’
Oprah Winfrey says taking a GLP-1 drug such as Ozempic and Wegovy has changed her entire perspective on “thin people.” The media icon, 70, took to her podcast last week to share her experience with an undisclosed type of GLP-1 drug that she began taking in 2023.
Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.
Not Just For Weight Loss: GLP-1 Drugs May Affect Addiction And Dementia Risk
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.
The Health Risks and Benefits of Weight-Loss Drugs
T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine,
What Oprah Winfrey Learned About “Thin People” After Weight-Loss Drug Experience
Oprah Winfrey opens up on her podcast about her weight-loss journey with anti-obesity GLP-1 medications while chatting with doctors and guests. Plus, the media icon shares how her opinion of "thin people" has changed.
Oprah Winfrey Slammed for Claiming 'Thin People' Aren't Thinking About Food After Taking Weight-Loss Drug
Oprah Winfrey is opening up about her experience taking weight-loss drug GLP-1. While speaking to guest Dr. Ania Jastreboff on the Tuesday, January 21, episode of “The Oprah Podcast," the talk-show host spilled,
The Internet is Coming for Oprah Because of Her Comments About Thin People and Weight Loss Drugs
The media mogul is being criticized by some for statements she made about thin people on the latest episode of her podcast.
Oprah Winfrey reveals shocking discovery after using weight-loss drug: 'They are not even thinking about it'
Oprah Winfrey is opening up about her experience using weight-loss drugs. The media mogul is sharing some of the realizations she has found after being under an undisclosed GLP-1, which is a type 2 diabetes medication that results in weight loss.
What changed Oprah Winfrey’s perception of thin people
Oprah Winfrey has changed her perceptions of "thin people" after taking weight loss medication. The 70-year-old talk show host has seen her
GLP-1 weight loss drugs linked to a wide range of health benefits and risks: study
A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, ...
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
Medical News Today4d
GLP-1 drugs linked to lower dementia risk, higher risk of kidney, stomach issues
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
WGN Radio5h
Ozempic and similar weight loss drugs may lower risk of 42 health conditions, but also pose risks
The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...
Demand for loose skin surgery rises with GLP-1 weight loss meds
As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity, doctors are observing a surge in patients ...
Popular Weight Loss Drugs Could Affect Your Behavior: Scientists Conduct Genetic Investigation
A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.
Neuroscience News5d
GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks
A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like ...
Novo Nordisk reports 22% weight loss in early subcutaneous amycretin trial
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...
Ozempic and Wegovy: Scientists Uncover New Risks of Popular Weight-Loss “Miracle Drugs”
GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...